RNA sequencing is considered the gold standard for high-throughput profiling of gene expression at the transcriptional level. Its increasing importance in cancer research and molecular diagnostics is reflected in the growing number of its mentions in scientific literature and clinical trial reports. However, the use of different reagents and protocols for RNA sequencing often produces incompatible results. Recently, we published the Oncobox Atlas of RNA sequencing profiles for normal human tissues obtained from healthy donors killed in road accidents. This is a database of molecular profiles obtained using uniform protocol and reagents settings that can be broadly used in biomedicine for data normalization in pathology, including cancer. Here, we publish new original 39 breast cancer (BC) and 19 lung cancer (LC) RNA sequencing profiles obtained for formalin-fixed paraffin-embedded (FFPE) tissue samples, fully compatible with the Oncobox Atlas. We performed the first correlation study of RNA sequencing and immunohistochemistry-measured expression profiles for the clinically actionable biomarker genes in FFPE cancer tissue samples. We demonstrated high (Spearman's rho 0.65-0.798) and statistically significant (p < 0.00004) correlations between the RNA sequencing (Oncobox protocol) and immunohistochemical measurements for HER2/ERBB2, ER/ESR1 and PGR genes in BC, and for PDL1 gene in LC; AUC: 0.963 for HER2, 0.921 for ESR1, 0.912 for PGR, and 0.922 for PDL1. To our knowledge, this is the first validation that total RNA sequencing of archived FFPE materials provides a reliable estimation of marker protein levels. These results show that in the future, RNA sequencing can complement immunohistochemistry for reliable measurements of the expression biomarkers in FFPE cancer samples.
Keywords: NCT03521245; RNA sequencing; bioinformatics; biomarkers detection; breast cancer; clinical oncology; immunohistochemistry; lung cancer; molecular diagnostics; personalized medicine; targeted therapies; transcriptomics; trastuzumab.
Conflict of interest statement
M.S. (Maxim Sorokin), A.G. and A.B. have a financial relationship with OmicsWay Corp. OmicsWay Corp. was not involved in the study design, collection, analysis, and interpretation of data. The remaining authors have nothing to disclose.
Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.BMC Cancer. 2016 Jul 7;16:398. doi: 10.1186/s12885-016-2476-x. BMC Cancer. 2016. PMID: 27389414 Free PMC article.
Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform.Br J Cancer. 2011 Nov 8;105(10):1574-81. doi: 10.1038/bjc.2011.355. Br J Cancer. 2011. PMID: 22067903 Free PMC article.
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.Diagn Mol Pathol. 2011 Mar;20(1):1-10. doi: 10.1097/PDM.0b013e3181e3630c. Diagn Mol Pathol. 2011. PMID: 21326033
Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.Breast Cancer Res Treat. 2018 Nov;172(2):327-338. doi: 10.1007/s10549-018-4889-5. Epub 2018 Aug 17. Breast Cancer Res Treat. 2018. PMID: 30120700 Free PMC article.
mRNA-seq whole transcriptome profiling of fresh frozen versus archived fixed tissues.BMC Genomics. 2018 May 30;19(1):419. doi: 10.1186/s12864-018-4761-3. BMC Genomics. 2018. PMID: 29848287 Free PMC article.